Overview

Esomeprazole in PPI Failures - IMPROVE

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess how PPI treated GERD patients with insufficient symptom control will benefit from a change in management by providing a more efficient acid secretion inhibition during 4 weeks, by evaluation of esomeprazole 40 mg compared to pre-study PPI treatment.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Esomeprazole